European Heart Journal-Cardiovascular Pharmacotherapy

Papers
(The TQCC of European Heart Journal-Cardiovascular Pharmacotherapy is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients98
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study77
Early initiation of SGLT2 inhibitors after acute myocardial infarction69
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study64
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? Why can’t we see the evidence?60
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor48
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials48
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials46
Finerenone for Diabetic Hearts: A Critical Appraisal of MACE Benefits and the Research Road Ahead42
The role of aetiology in determining anticoagulation effectiveness for the treatment of left ventricular thrombus41
Implementation of novel antithrombotic treatment strategies and outcome improvements in patients with myocardial infarction and atrial fibrillation over 20 years: a nationwide cohort study37
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee37
Effectiveness and safety of sodium-glucose cotransporter-2 inhibitor initiation in sacubitril-valsartan users with heart failure: a population-based cohort study37
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis34
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study34
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study34
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy31
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia30
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’29
All about clinical trials27
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy26
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis26
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives26
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials25
New ways of mitigating aldosterone in cardiorenal disease25
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data25
SGLT2 inhibitors are associated with improved long-term survival in Takotsubo syndrome: insights from large-scale real-world data25
When Randomization Is Not Enough: Divergent Beta-Blocker Trials and the Illusion of Universal Causality23
Impact of left ventricular ejection fraction on the effect of beta-blocker therapy on 1-year mortality in acute coronary syndrome patients23
Anti-inflammatory pharmacotherapy in patients with cardiovascular disease23
Authors’ reply to: ‘preventing atrial fibrillation with SGLT2 inhibitors: time, sex, and substrate’ by Karakasis et al .23
De-escalation versus shortening of dual antiplatelet therapy21
Aspirin may take a back row seat for non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention21
OCEAN trial: rethinking long-term anticoagulation after atrial fibrillation ablation21
Long-term antiplatelet monotherapy after PCI: searching for the smart choice21
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis20
Cardiovascular prevention and risk factors20
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-20
Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease20
SGLT2 inhibitors in heart failure with tricuspid regurgitation: clinical interpretation and future directions19
Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic19
Net clinical benefit of extended dual pathway inhibition in chronic coronary syndrome as classified by the 2024 ESC criteria: a COMPASS substudy19
News in cardiovascular pharmacotherapy from the ACC.24 Meeting19
Correction to: Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial18
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results18
Chronic coronary syndrome and new-onset atrial fibrillation or venous thromboembolism: how best to manage antithrombotic therapy strategies17
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials17
Entering a new era of antiplatelet therapy: the 4D-ACS trial17
The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts17
Reply to ‘Sacubitril/valsartan in heart failure: a critical look at dementia risk and future study pathways’16
Pharmacotherapy of patients with heart failure and atrial fibrillation: let's get the evidence!16
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 202316
Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry15
Are NOACs always the best strategy in elderly AF patients?15
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis15
Focus on different aspects of atrial fibrillation15
Correction to: Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee14
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes14
Impact of single vs. dual local anaesthetic regimen on the efficacy and safety of percutaneous stellate ganglion block for electrical storm: new insights from the STAR study14
Initiation of eplerenone vs. spironolactone and all-cause mortality in HFrEF: linked database study14
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry14
What's new in pharmacotherapy at ESC Congress 2023?14
A farewell to professor Stefan Agewall from the ESC Working Group on Cardiovascular Pharmacotherapy14
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 202214
Seeking for the boundaries of de-escalation in antiplatelet therapy for acute coronary syndrome13
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?13
Different aspects of pharmacological heart failure treatment13
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation13
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?13
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study13
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis13
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis13
Cardiotoxicity in dual immune checkpoint inhibitors: a critical appraisal of signal interpretation and future directions12
Inotropes and mortality in patients with cardiogenic shock: an instrumental variable analysis from the SWEDEHEART registry12
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue12
Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark12
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr12
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials12
Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials12
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study12
An old drug in a new era: digitoxin in the spotlight after DIGIT-HF12
Corrigendum to: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharm11
We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists11
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study11
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease11
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial10
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study10
Kidney function and acid–base status as gatekeepers of natriuretic and diuretic responsiveness in chronic HF: insights from the DEA-HF clinical trial10
RNA-targeted therapeutics in cardiovascular disease: the time is now10
Intracoronary adjunctive therapies for ST-elevation myocardial infarction: a network meta-analysis of trials10
FLOW trial stopped early due to evidence of renal protection with semaglutide10
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial10
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study9
The ESC Working Group on cardiovascular pharmacotherapy: continuity through transformation9
2024 ESC Guidelines for the management of elevated blood pressure and hypertension: what is new in pharmacotherapy?9
Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding9
Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies9
News in cardiovascular pharmacotherapy from the ACC.25 Meeting9
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure9
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study9
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF9
0.15606713294983